CML, Folate, Treatment-free Remission
Conditions
Keywords
FOLR3, CML, TFR
Brief summary
For patients with chronic myeloid leukemia in chronic phase (CML-CP) who have achieved a stable deep molecular response (DMR) using BCR-ABL1 tyrosine kinase inhibitors (TKIs), treatment-free remission (TFR) following TKI cessation is an emerging goal. However, about half of the patients relapsed after TKI discontinuation. There is no definite examinations to predict the outcome of TKI discontinuation. Investigators aim to study the relationship between FLOR3 SNP rs139130389 and the outcome of TKI discontinuation.
Detailed description
Investigators aim to detect FOLR3 SNP rs139130389, and establish its correlation with patients' treatment response, remission time, TKI resistance and the outcome of TKI stopping.
Interventions
None listed
Sponsors
Affiliated Hospital of Nantong University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
1. The patient signs the informed consent form 2. Age over 18, male or female 3. The patient was diagnosed as chronic phase of CML. 4. ECoG score 0-2 5. Receive TKI treatment for at least 4 years and continuously obtain MR4 or mr4.5 for at least 3 years. 6. The subjects fully understand and comply with the requirements of the research scheme and are willing to complete the research as planned.
Exclusion criteria
NA
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| treatment-free remission or relapse | 1 year | Observe whether the patients were in remission or relapse 1 year after drug withdrawal |
Countries
China
Contacts
Primary ContactHong Liu, Doctorate
Backup ContactLu Zhou, Doctorate
Outcome results
None listed